
According to Reuters, two pharmaceutical companies were fined by China’s market regulator for engaging in monopolistic behavior.
Grand Pharmaceutical was fined 136 million yuan ($19.68 million) and had 149 million yuan of “illegal revenue” confiscated for engaging in a monopolistic agreement with Wuhan Healthcare Pharmaceuticals.
Related: UK: CMA accuses pharma firms of market allocation
Wuhan Healcare Pharmaceuticals was fined 4.13 million yuan by the regulator and had slightly over 30 million yuan of its revenue confiscated.
In recent months, Chinese regulatory authorities have initiated antitrust investigations on various sectors, with a particular focus on technology corporations, including Alibaba Group.
Featured News
Boeing to Sell Key Digital Aviation Units to Thoma Bravo in $10.55 Billion Deal
Apr 22, 2025 by
CPI
Claus-Dieter Ehlermann, Key Figure in EU Antitrust Policy, Dies at 94
Apr 22, 2025 by
CPI
Instagram Co-Founder Claims Zuckerberg Starved It of Resources After Acquisition
Apr 22, 2025 by
CPI
Binance Advises Governments on Crypto Rules and Digital Asset Reserves
Apr 22, 2025 by
CPI
OpenAI Eyes Chrome If DOJ Forces Google to Sell Browser, Exec Testifies
Apr 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece